<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01858623</url>
  </required_header>
  <id_info>
    <org_study_id>PPT5</org_study_id>
    <nct_id>NCT01858623</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Interactions of Losartan and Hydrochlorothiazide</brief_title>
  <acronym>PKLH</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Damanhour University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Damanhour University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was conducted to investigate any potential reaction between losartan and
      hydrochlorothiazide.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Heart rate</measure>
    <time_frame>Participants will be followed for the duration of study, an expected average of 5 weeks.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Participants will be monitored for the duration of study, an expected average of 5 weeks.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter such as Cmax of losartan and hydrochlorothiazide</measure>
    <time_frame>At the end of the study, after collection of all blood samples, an expected average of 4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter such as AUC of losartan and hydrochlorothiazide</measure>
    <time_frame>At the end of the study, after collection of all blood samples, an expected average of 4 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Healthy Normotensive Participants</condition>
  <arm_group>
    <arm_group_label>Losartan / Hydrochlorothiazide100 mg/25mg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Losartan / Hydrochlorothiazide100 mg/25mg fixed dose combination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Losartan 100 mg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Losartan 100 mg alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hydrochlorothiazide 25 mg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>hydrochlorothiazide 25 mg alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan/hydrochlorothiazide</intervention_name>
    <arm_group_label>Losartan / Hydrochlorothiazide100 mg/25mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <arm_group_label>Losartan 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrochlorothiazide</intervention_name>
    <arm_group_label>hydrochlorothiazide 25 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years old and not more than 45 healthy male volunteers

          -  Who had passed all the screening parameters

        Exclusion Criteria:

          -  A clinically significant abnormal physical exam, medical history, or laboratory
             studies

          -  If they showed a sitting SBP of &gt;140 or &lt;100 mmHg, DBP &gt; 90 or &lt;60mm Hg, or a pulse
             rate of &gt; 95 or &lt; 50 beats/min at screening

          -  The use of any prescription drug within the previous month or use of any
             over-the-counter medication within the past 14 days

          -  A history of blood dyscrasias

          -  A history of alcohol or drug abuse within the past year

          -  Donation of blood during the 8 weeks prior to the study or plans to donate blood
             during or within 8 weeks of completing the study

          -  Unable to tolerate vein puncture and multiple blood samplings

          -  Any surgical/medical condition that might alter drug absorption, distribution,
             metabolism, or excretion
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2013</study_first_submitted>
  <study_first_submitted_qc>May 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2013</study_first_posted>
  <last_update_submitted>May 24, 2013</last_update_submitted>
  <last_update_submitted_qc>May 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Damanhour University</investigator_affiliation>
    <investigator_full_name>Sally Helmy, PhD, CPHQ</investigator_full_name>
    <investigator_title>Lecturer of Pharmaceutics, Faculty of Pharmacy</investigator_title>
  </responsible_party>
  <keyword>Healthy Normotensive Participants</keyword>
  <keyword>Fixed dose combination</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Losartan</keyword>
  <keyword>Hydrochlorothiazide</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

